Beyond The Numbers: 11 Analysts Discuss ACADIA Pharmaceuticals Stock

In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide array of perspectives from bullish to bearish. Latest Ratings for ACAD Date Firm Action From To Mar 2022 Cantor Fitzgerald Maintains Overweight Mar 2022 Goldman Sachs Maintains Neutral Mar 2022 Mizuho Maintains Neutral View More Analyst Ratings…

Read More